Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K D Lewis

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
The British Journal of Dermatology|September 24, 2019
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT studyR Dummer, A Guminksi, R Gutzmer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 29, 2017
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT studyJ T Lear, M R Migden, K D Lewis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitorsK D Lewis, K Peris, A Sekulic, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
The British Journal of Dermatology|September 24, 2019
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT studyR Dummer, A Guminksi, R Gutzmer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 29, 2017
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT studyJ T Lear, M R Migden, K D Lewis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitorsK D Lewis, K Peris, A Sekulic, et al.
Pageof 3